Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

Teclegiorgis Gebremariam, Sondus Alkhazraji, Lin Lin, Nathan P. Wiederhold, Edward P. Garvey, William J. Hoekstra, Robert J. Schotzinger, Thomas F. Patterson, Scott G. Filler, Ashraf S. Ibrahim

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.

Original languageEnglish (US)
Article numbere00390-17
JournalAntimicrobial agents and chemotherapy
Volume61
Issue number9
DOIs
StatePublished - Sep 2017

Keywords

  • Mucormycosis
  • Murine
  • Prophylaxis
  • Rhizopus arrhizus
  • VT-1161

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection'. Together they form a unique fingerprint.

  • Cite this

    Gebremariam, T., Alkhazraji, S., Lin, L., Wiederhold, N. P., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2017). Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection. Antimicrobial agents and chemotherapy, 61(9), [e00390-17]. https://doi.org/10.1128/AAC.00390-17